10-Q: Avenue Therapeutics Reports Q1 2024 Results, Faces Going Concern Uncertainty

Avenue Therapeutics reported a net loss of $4.3 million for Q1 2024 and faces substantial doubt about its ability to continue as a going concern.

Summary

• Avenue Therapeutics reported a net loss of $4.3 million for the first quarter of 2024, compared to a net loss of $7.6 million for the same period in 2023.
• The company's research and development expenses increased to $2.4 million, up from $1.2 million in the prior year, primarily due to increased clinical study expenses for AJ201.
• General and administrative expenses also rose to $1.3 million from $1.0 million year-over-year, driven by higher professional fees and non-cash stock compensation costs.
• The company's cash and cash equivalents stood at $3.2 million as of March 31, 2024, compared to $1.8 million at the end of 2023.
• Avenue Therapeutics has an accumulated deficit of $95.3 million as of March 31, 2024.
• The company completed a 1-for-75 reverse stock split on April 26, 2024.
• The company is actively working to regain compliance with Nasdaq listing requirements, including minimum stockholders' equity and bid price rules.
• The company is dependent on raising additional capital to fund operations and has stated that without additional capital, they do not expect their cash to be sufficient to fund their projected operating requirements past the third quarter of 2024.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the company's significant net loss, going concern uncertainty, and reliance on additional funding. While there are some positive developments, such as the completion of enrollment for the AJ201 trial and the agreement with the FDA on the IV tramadol study, the overall financial situation and the risk of delisting from Nasdaq overshadow these positives.

Positives

• The net loss decreased from $7.6 million in Q1 2023 to $4.3 million in Q1 2024.
• Cash and cash equivalents increased to $3.2 million as of March 31, 2024.
• The company successfully completed a warrant inducement offering in January 2024, raising $4.5 million.
• The company has completed enrollment for the Phase 1b/2a trial of AJ201 and expects topline data midyear 2024.
• The company reached final agreement with the FDA on the Phase 3 safety study protocol for IV tramadol.

Negatives

• The company reported a net loss of $4.3 million for Q1 2024.
• The company has an accumulated deficit of $95.3 million.
• The company has stated that without additional capital, they do not expect their cash to be sufficient to fund their projected operating requirements past the third quarter of 2024.
• The company faces substantial doubt about its ability to continue as a going concern.
• The company is not yet generating revenue and expects to continue to incur significant operating losses.
• The company is reliant on raising additional capital to fund operations.
• The company is working to regain compliance with Nasdaq listing requirements.

Risks

• The company's ability to continue as a going concern is in substantial doubt due to ongoing losses and the need for additional funding.
• The company may not be able to secure additional funding on acceptable terms, or at all.
• The company is reliant on third parties for several aspects of its operations.
• The company's product candidates may not receive regulatory approval or be successfully commercialized.
• The company is subject to potential product liability claims.
• The company may not be able to maintain sufficient patent protection for its technology and products.
• The company is reliant on Fortress Biotech, Inc. for a majority of the voting power of its outstanding capital stock and has rights to receive significant share grants annually.
• The company is working to regain compliance with Nasdaq listing requirements and may be delisted if it fails to do so.

Future Outlook

The company expects to continue to incur substantial losses from operations for the foreseeable future as it continues the development of its product candidates. The company intends to obtain additional capital through the sale of debt or equity securities or other arrangements to fund its operations, research and development activity or regulatory approval activity. The company does not expect its cash will be sufficient to fund its projected operating requirements past the third quarter of 2024 without additional capital.

Management Comments

• The company is focused on the development and commercialization of therapies for the treatment of neurologic diseases.
• The company is working to regain compliance with Nasdaq listing requirements.
• The company is actively seeking additional funding to support its operations and development programs.

Industry Context

Avenue Therapeutics is operating in the competitive pharmaceutical industry, focusing on developing treatments for neurologic diseases. The company's pipeline includes AJ201 for SBMA, IV tramadol for post-operative pain, and BAER-101 for epilepsy and panic disorders. The company's financial results and going concern uncertainty highlight the challenges faced by early-stage biotech companies in bringing new therapies to market. The company's reliance on external funding and regulatory approvals is typical of the industry.

Comparison to Industry Standards

• Avenue Therapeutics' Q1 2024 net loss of $4.3 million is not unusual for a clinical-stage biotech company, but the substantial doubt about its ability to continue as a going concern is a significant concern.
• Compared to other companies in the sector, Avenue's cash position of $3.2 million is relatively low, especially given its ongoing clinical trials and need for additional funding.
• The increase in R&D expenses to $2.4 million reflects the company's focus on advancing its clinical programs, which is consistent with industry trends for companies in similar stages of development.
• The company's reliance on warrant inducements and private placements for funding is a common practice for smaller biotech companies, but it also indicates a potential lack of access to more traditional financing options.
• The company's efforts to regain compliance with Nasdaq listing requirements are a common challenge for companies with low stock prices and limited market capitalization, and the reverse stock split is a typical measure to address this issue.
• Companies like Biohaven Pharmaceutical and Sage Therapeutics, which also focus on neurological disorders, have faced similar challenges in funding and regulatory approvals, but they have generally had stronger cash positions and more advanced pipelines.

Related Party Transactions

• The company recorded expenses related to the Management Services Agreement with Fortress Biotech, Inc. of $0.1 million for both the three months ended March 31, 2024 and 2023.
• The company issued common stock to Fortress Biotech, Inc. as a Financing Equity Fee and Annual Equity Fee.
• The company has a Founders Agreement and Management Services Agreement with Baergic Bio, Inc.

Stakeholder Impact

• Shareholders face significant risk due to the company's going concern uncertainty and potential delisting from Nasdaq.
• Employees may be impacted by potential cost-cutting measures or restructuring if the company fails to secure additional funding.
• Customers and patients may be affected by delays or discontinuation of clinical trials and product development if the company's financial situation does not improve.
• Suppliers and creditors may face increased risk of non-payment if the company's financial situation deteriorates.

Next Steps

• The company plans to initiate the Phase 3 safety study for IV tramadol as soon as possible, subject to having the necessary financing.
• The company expects topline data from the Phase 1b/2a trial of AJ201 midyear 2024.
• The company will continue to seek additional funding through various means.
• The company will continue to work to regain compliance with Nasdaq listing requirements.

Key Dates

Keywords

Avenue Therapeutics, ATXI, Pharmaceutical, Biotechnology, Clinical Trials, AJ201, IV Tramadol, BAER-101, Neurologic Diseases, Reverse Stock Split, Nasdaq Compliance, Warrant Inducement, Going Concern